Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.45 |
| ▸ | FAP | Q12884 | 4/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337493 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23781698 | 0.93 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23781697 | 0.93 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL24011941 | 0.93 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2408415 | 0.85 | OPRM1 (0.48) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2186454 | 0.83 | F2 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL26429190 | 0.83 | F2 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL11605575 | 0.83 | F2 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5178008 | 0.83 | DPP4 (0.48) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL11643093 | 0.83 | F2 (0.40) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2009-07-02 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060188920-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | BALZARINI JAN MARIA R | 2006-08-24 | — | — | US | disclosed |
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | BALZARINI JAN MARIA R | 2006-08-17 | — | — | US | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| EP-1603546-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | Tripep AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | TRIPEP AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | GALE, ENGASE, GLMN | DPP4 625/4885DPP8 403/4885DPP9 664/4885 |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | GALE, ENGASE, GLMN | DPP4 449/4885DPP8 202/4885DPP9 679/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | DPP4 725/4885DPP8 533/4885DPP9 819/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | DPP4 380/4885DPP8 213/4885DPP9 401/4885 |
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | OGA, ENGASE, GALE | DPP4 320/4885DPP8 275/4885DPP9 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.